Chronic Obstructive Pulmonary Disease (COPD)

The objective of the Chronic Obstructive Pulmonady Disease (COPD) study is to demonstrate the superiority of the combination of indacaterol and open label tiotropium to tiotropium alone in the treatment of patients with moderate-to-severe COPD.

Who is Eligible to Participate?

Male and Female adults aged 40 years and older with diagnosed moderate to severe COPD.

What is Involved?

This is a randomized, double-blind, controlled, parallel group so one group will receive the study medication (indacterol) and the other group will receive a placebo. The participants will be asked to make 9 visits to the clinic over a 12 week period. During the 12 weeks they will be asked to use the study medication/placebo and keep a diary of their drug use and asthma symptoms. There will some lab work drawn at various points during the study as well as pulmonary function studies performed.

  

Study Details Principal Investigator        Arnold B. Gorin, MD  Sub-Investigator        Eric Schroeder, MD  Study Coordinator        Mary Lou Schroeder, RN Trial Status        Pending - Apply Now Study Length        12 weeks